Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial [Sarcomas]

Conclusion
Three years of adjuvant imatinib therapy results in longer survival than 1 year of imatinib. High 5-year survival rates are achievable in patient populations with high-risk GIST.

Source: Journal of Clinical Oncology - January 12, 2016 Category: Cancer & Oncology Authors: Joensuu, Eriksson, Sundby Hall, Reichardt, Hartmann, Pink, Ramadori, Hohenberger, Al-Batran, Schlemmer, Bauer, Wardelmann, Nilsson, Sihto, Bono, Kallio, Junnila, Alvegard, Reichardt Tags: Chemotherapy Sarcomas Source Type: research